Kamada Launches Two New Biosimilars in Israel, Targets $25M Annual Revenue by 2030
KMDA sits 24% above its 52-week low of $6.5.
Summary
Kamada launched Ustekinumab-Kamada and Enoxaparin-Kamada in Israel, doubling its biosimilar portfolio to four marketed products. The company provided multi-year revenue guidance for the biosimilar segment: approximately $4 million in 2026, $10 million in 2028, and $20-25 million by 2030, with at least 12 products expected from 6 licensing partners. This follows the 6-K filed today and builds on the company's stated strategic growth pillar of in-licensing biosimilars for Israel and MENA. The launch adds two interchangeable products in immunology and anticoagulation, expanding Kamada's commercial footprint beyond its core plasma-derived therapies. The revenue targets represent a meaningful but gradual contribution relative to Kamada's overall revenue base, with the 2030 goal implying a significant ramp from current levels.
Updates
· SEC 6-K — The 6-K attaches the press release announcing the launch and revenue targets.
At the time of this announcement, KMDA was trading at $8.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $461.6M. The 52-week trading range was $6.50 to $9.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.